Is PR Pharma's Biggest Challenge? with John LaMattina


Podcast brought to you by: Chempetitive Group - "We love science. We love marketing. We love the idea of combining the two to make great things happen for your marketing communications."

Guests:

John LaMattina, PhD, Former Head of Research, Pfizer

Bio and Contact Info

Listen (3:36) Pharma's PR challenge

Listen (5:48) When did public perception change for the worse?

Listen (2:27) Astronauts are heroes, why not drug chemists?

Listen (5:06) What can the industry do about poor image?

Listen (10:51) Open data a win-win

Listen (8:21) Raising the bar means more failures

If astronauts can be heroes, asks John LaMattina, former head of R & D at Pfizer, why not drug chemists? It's a great question.

In the last ten years, big pharma companies have gone from being some of the most respected public companies in the U.S. to some of the public's least favorite. What happened? Since retiring from Pfizer in 2007, John has been focused on this question and what can be done to improve the image of the drug industry. He has authored two books, first, Drug Truths: Dispelling the Myths of R & D, and his more recent Devalued and Detrusted: Can the Pharmaceutical Industry Restore Its Broken Image?

When industry veterans retire, it can be good for the industry. They are free to talk about its problems. John says the industry must become more open and transparent. And he's eager to tell the stories of the industry's heroes.



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup